Literature DB >> 7881415

Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma.

K Foster1, A Prowse, A van den Berg, S Fleming, M M Hulsbeek, P A Crossey, F M Richards, P Cairns, N A Affara, M A Ferguson-Smith.   

Abstract

Loss of heterozygosity (LOH) studies have suggested that somatic mutations of a tumour suppressor gene or genes on chromosome 3p are a critical event in the pathogenesis of non-familial renal cell carcinoma (RCC). Germline mutations of the von Hippel-Lindau (VHL) disease gene predispose to early onset and multifocal clear cell renal cell carcinoma, and the mechanism of tumorigenesis in VHL disease is consistent with a one-hit mutation model. To investigate the role of somatic VHL gene mutations in non-familial RCC, we analysed 99 primary RCC for VHL gene mutations by SSCP and heteroduplex analysis. Somatic VHL gene mutations were identified in 30 of 65 (46%) sporadic RCC with chromosome 3p allele loss and one of 34 (3%) tumours with no LOH for chromosome 3p. The VHL gene mutations were heterogeneous (17 frameshift deletions, eight missense mutations, four frameshift insertions, one nonsense and one splice site mutation), but no mutations were detected in the first 120 codons of cloned coding sequence. Most RCCs with somatic VHL mutations (23 of 27 (85%) informative cases) had chromosome 3p25 allele loss in the region of the VHL gene so that both alleles of the VHL gene had been inactivated as expected from a two-hit model of tumorigenesis. Detailed histopathology was available for 59 of the tumours investigated: 18 of 43 (42%) RCC with a clear cell appearance had a somatic VHL gene mutation but none of 16 non-clear cell RCC (eight chromophilic, three chromophobe and five oncocytoma) (chi2 = 7.77, P < 0.025).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1994        PMID: 7881415     DOI: 10.1093/hmg/3.12.2169

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  96 in total

1.  The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity.

Authors:  D Mukhopadhyay; B Knebelmann; H T Cohen; S Ananth; V P Sukhatme
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

Review 2.  HIF hydroxylation and the mammalian oxygen-sensing pathway.

Authors:  Michal Safran; William G Kaelin
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

3.  Allelic deletion and mutation of the von Hippel-Lindau (VHL) tumor suppressor gene in pancreatic microcystic adenomas.

Authors:  A O Vortmeyer; I A Lubensky; F Fogt; W M Linehan; U Khettry; Z Zhuang
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

4.  An alternative route for multistep tumorigenesis in a novel case of hereditary renal cell cancer and a t(2;3)(q35;q21) chromosome translocation.

Authors:  D Bodmer; M J Eleveld; M J Ligtenberg; M A Weterman; B A Janssen; D F Smeets; P E de Wit; A van den Berg; E van den Berg; M I Koolen; A Geurts van Kessel
Journal:  Am J Hum Genet       Date:  1998-06       Impact factor: 11.025

Review 5.  Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy.

Authors:  E Jason Abel; Christopher G Wood
Journal:  Nat Rev Urol       Date:  2009-06-16       Impact factor: 14.432

Review 6.  The von Hippel-Lindau gene: turning discovery into therapy.

Authors:  Peter E Clark; Michael S Cookson
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

7.  Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein.

Authors:  S Lee; M Neumann; R Stearman; R Stauber; A Pause; G N Pavlakis; R D Klausner
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

8.  Influence of the RNA-binding protein HuR in pVHL-regulated p53 expression in renal carcinoma cells.

Authors:  Stefanie Galbán; Jennifer L Martindale; Krystyna Mazan-Mamczarz; Isabel López de Silanes; Jinshui Fan; Wengong Wang; Jochen Decker; Myriam Gorospe
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

9.  Evidence for aldosterone-dependent growth of renal cell carcinoma.

Authors:  Sharon King; Susan Bray; Sarah Galbraith; Lesley Christie; Stewart Fleming
Journal:  Int J Exp Pathol       Date:  2014-05-07       Impact factor: 1.925

10.  Detection of a germline mutation and somatic homozygous loss of the von Hippel-Lindau tumor-suppressor gene in a family with a de novo mutation. A combined genetic study, including cytogenetics, PCR/SSCP, FISH, and CGH.

Authors:  H J Decker; C Neuhaus; A Jauch; M Speicher; T Ried; M Bujard; H Brauch; S Störkel; M Stöckle; B Seliger; C Huber
Journal:  Hum Genet       Date:  1996-06       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.